These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11577586)

  • 1. [mTOR and FTY 720 inhibitors].
    Morel D
    Presse Med; 2001 Sep; 30(24 Pt 2):35-7. PubMed ID: 11577586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD.
    Schuurman HJ; Menninger K; Audet M; Kunkler A; Maurer C; Vedrine C; Bernhard M; Gaschen L; Brinkmann V; Quesniaux V
    Transplantation; 2002 Oct; 74(7):951-60. PubMed ID: 12394836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY-720 is efficacious in monkey kidney transplantation.
    Quesniaux V; Menninger K; Audet M; Gaschen L; Schuurman HJ
    Transplant Proc; 2001 May; 33(3):2374-5. PubMed ID: 11377564
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunosuppressive drugs in paediatric liver transplantation.
    van Mourik ID; Kelly DA
    Paediatr Drugs; 2001; 3(1):43-60. PubMed ID: 11220404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exposure-efficacy relationships of a fingolimod-everolimus regimen in kidney transplant patients at risk for delayed graft function.
    Kovarik JM; Tedesco-Silva H; Lorber MI; Foster C
    Transplant Proc; 2006 Dec; 38(10):3479-82. PubMed ID: 17175310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [New immunodepressant drugs for the prevention and control of kidney transplant rejection].
    Segoloni GP
    G Ital Nefrol; 2005; 22(1):3-15. PubMed ID: 15786373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus: new preparation. No tangible advance in renal transplantation.
    Prescrire Int; 2002 Dec; 11(62):165-6. PubMed ID: 12469693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pros and the cons of mTOR inhibitors in kidney transplantation.
    Ponticelli C
    Expert Rev Clin Immunol; 2014 Feb; 10(2):295-305. PubMed ID: 24377908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus.
    Kahan BD
    Ther Drug Monit; 2002 Feb; 24(1):47-52. PubMed ID: 11805722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of transplant rejection: are the traditional immunosuppressants good enough?
    Dumont FJ
    Curr Opin Investig Drugs; 2001 Mar; 2(3):357-63. PubMed ID: 11575705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
    Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
    Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Future immunosuppressive agents in solid-organ transplantation.
    Gabardi S; Cerio J
    Prog Transplant; 2004 Jun; 14(2):148-56. PubMed ID: 15264459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus in clinical practice in long-term liver transplantation: an observational study.
    Casanovas T; Argudo A; Peña-Cala MC
    Transplant Proc; 2011; 43(6):2216-9. PubMed ID: 21839237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine.
    Shihab FS; Cibrik D; Chan L; Kim YS; Carmellini M; Walker R; Zibari G; Pattison J; Cornu-Artis C; Wang Z; Tedesco-Silva H
    Clin Transplant; 2013; 27(2):217-26. PubMed ID: 23230975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.
    Schweiger M; Wasler A; Prenner G; Stiegler P; Stadlbauer V; Schwarz M; Tscheliessnigg K
    Transpl Immunol; 2006 Jun; 16(1):46-51. PubMed ID: 16701176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection.
    Cowan PA; Heizer KE
    Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 exerts differential effects on CD4+ and CD8+ T-lymphocyte subpopulations expressing chemokine and adhesion receptors.
    Böhler T; Waiser J; Schuetz M; Neumayer HH; Budde K
    Nephrol Dial Transplant; 2004 Mar; 19(3):702-13. PubMed ID: 14767029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Benefit-risk assessment of sirolimus in renal transplantation.
    Kuypers DR
    Drug Saf; 2005; 28(2):153-81. PubMed ID: 15691225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 (fingolimod) in renal transplantation.
    Budde K; Schütz M; Glander P; Peters H; Waiser J; Liefeldt L; Neumayer HH; Böhler T
    Clin Transplant; 2006; 20 Suppl 17():17-24. PubMed ID: 17100697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.